This is a Norway news story, published by Investor's Business Daily, that relates primarily to Moderna news.
For more Norway news, you can click here:
more Norway newsFor more Moderna news, you can click here:
more Moderna newsFor more vaccine development news, you can click here:
more vaccine development newsFor more news from Investor's Business Daily, you can click here:
more news from Investor's Business DailyOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like this article about vaccine development, you might also like this article about
Moderna stock. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest vaccine supplies news, Moderna shares news, news about vaccine development, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Moderna Stock YoInvestor's Business Daily
•
87% Informative
Moderna (MRNA) won an agreement for its Covid vaccines in Europe on Friday .
The agreement provides 17 countries in the European Union , Norway and North Macedonia with access to Moderna 's messenger RNA -based Covid vaccine for up to four years .
That includes prefilled syringes, which can speed up vaccinations on a pharmacy-by-pharmacy basis.
VR Score
86
Informative language
83
Neutral language
89
Article tone
formal
Language
English
Language complexity
56
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
8
Source diversity
3
Affiliate links
no affiliate links